Answers are grounded in this paper and cite their sources.
This research identifies lymphotoxin beta receptor's role in chronic pain management, suggesting therapeutic targets.
Preventing the development of chronic pain is crucial to avoiding difficult-to-manage, debilitating pain conditions. Our research identifies the lymphotoxin beta receptor (LTβR) as a peripheral master regulator in this process. Activation of LTβR induces mechanical allodynia and increases sensory neuron excitability by engaging peripheral non-neuronal cells, including macrophages and stromal cells. Conversely, local blockade of LTβR reduces neuronal hyperexcitability and irreversibly prevents chronic pain in a neuropathic preclinical model. These LTβR effects are driven by both LTβ and LIGHT. Transcriptomic analysis reveals that LTβR regulates the development of chronic pain by coordinating a peripheral gene-plasticity network that involves immune-related genes and diverse cell types. Overall, LTβR acts as a master regulator controlling the development of pain chronicity by shaping a peripheral gene plasticity network that drives sensory neuronal sensitization.
No takes yet. Share an insight, caveat, or question.
Tumanov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: